We aimed at assessing the prevalence of peripheral neuropathy in newly diagnosed, treatment-naïve patients with multiple myeloma. We enrolled 153 patients with multiple myeloma at initial diagnosis. All patients underwent neurological examination and nerve conduction study. Patients with suspected pure small fiber neuropathy underwent skin biopsy. Of the 153 patients included in this study, 7.2 % had a multiple myeloma-related neuropathy. All patients suffered from a distal symmetric sensory peripheral neuropathy, associated with age (P = 0.04). Our study on prevalence rate of multiple myeloma-related peripheral neuropathy might provide a basis for improving the clinical management of this condition
The launch of novel chemotherapeutic agents—in particular, proteasome inhibitors and immunomodulator...
Introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and l...
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) may negatively influence multiple myeloma ...
MULTIPLE MYELOMA AND ITS TREATMENT ALTER PERIPHERAL NERVOUS SYSTEM STRUCTURE AND FUNCTION Alyssa Ka...
Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treat...
BACKGROUND: Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (...
BACKGROUND: Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (...
Purpose: Peripheral neuropathy (PN) is common in patients with multiple myeloma (MM). We hypothesize...
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...
Multiple myeloma (MM) is a B cell neoplasm characterized by uncontrolled growth of malignant plasma ...
International audienceBortezomib is a pivotal drug for the management of multiple myeloma. However, ...
Multiple sclerosis (MS) is the most common cause of disability after trauma in young adults in North...
Background: Peripheral neuropathy (PN), the most common complication during thalidomide (TD) treatm...
The launch of novel chemotherapeutic agents—in particular, proteasome inhibitors and immunomodulator...
Introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and l...
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) may negatively influence multiple myeloma ...
MULTIPLE MYELOMA AND ITS TREATMENT ALTER PERIPHERAL NERVOUS SYSTEM STRUCTURE AND FUNCTION Alyssa Ka...
Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treat...
BACKGROUND: Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (...
BACKGROUND: Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (...
Purpose: Peripheral neuropathy (PN) is common in patients with multiple myeloma (MM). We hypothesize...
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...
The aim of this analysis is to assess (1) self-reported chemotherapy-induced peripheral neuropathy (...
Multiple myeloma (MM) is a B cell neoplasm characterized by uncontrolled growth of malignant plasma ...
International audienceBortezomib is a pivotal drug for the management of multiple myeloma. However, ...
Multiple sclerosis (MS) is the most common cause of disability after trauma in young adults in North...
Background: Peripheral neuropathy (PN), the most common complication during thalidomide (TD) treatm...
The launch of novel chemotherapeutic agents—in particular, proteasome inhibitors and immunomodulator...
Introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and l...
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) may negatively influence multiple myeloma ...